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ORIGINAL ARTICLE
Background/Aims: Although the incidence of T-cell non-Hodgkin’s lymphoma (NHL) is higher in Far East Asia
than in Western countries, its incidence and clinical course in Korea are not well-defined. Therefore, we
assessed the relative frequency and clinical features of T-cell NHL in Korea.
Methods: We performed a retrospetcive analysis of 586 patients with NHL.
Results: 101 (17.2%) had T-cell NHL. The most frequent subtypes of T-cell NHL were extranodal NK/T-cell
lymphoma, nasal type (NASAL), peripheral T-cell lymphoma, unspecified type (PTCL-U), and anaplastic large
cell lymphoma, T/null cell, primary systemic type (ALCL). The seven pathological subtypes could be classified
into three prognostic subgroups. When patients with the three most frequent subtypes were grouped together,
their survival was reflected in the International Prognostic Index (IPI) scores. Univariate analysis of IPI elements
and other clinical features showed that clinical stage and extranodal sites were significant predictors of survival.
Cox multivariate analysis showed that the number of extranodal sites was the only independent prognostic
indicator.
Conclusions: The relative frequency of T-cell NHL seems to be decreasing in Korea, although NASAL remains
frequent. Korean patients with ALCL appear to have an unfavorable prognosis. Large-scale studies are
warranted for Korean patients with T-cell NHL. (Korean J Intern Med 2009;24:128-134)
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INTRODUCTION
Non-Hodgkin’s lymphoma (NHL) is a malignancy that
arises from lymphoid tissue. In the United States, NHL is
the fifth most commonly diagnosed cancer, accounting for
4% of all cancers, with an estimated 66,120 new cases and
19,160 deaths in 2008. Although the incidence of NHL
has stabilized, it is still increasing by 1-2% annually [1].
NHL is more frequent in the elderly than in younger
patients and more frequent in men than in women [2].
The incidence of NHL and the patterns of occurrence
of its various subtypes vary geographically. According to
the World Health Organization International Agency for
Research on Cancer (IARC), the rate of NHL is increasing
worldwide and is higher in developed countries than in
Africa and Asia [3]. The relative frequencies of the various
histopathological types of NHL are generally similar
among Asian countries. Compared to the United States,
Asian countries, including those in the Far East, have
higher rates of aggressive NHL, T-cell NHL, and extranodal
(EN) diseases [1,4-6].
T-cell NHL is a relatively uncommon malignancy,
accounting for approximately 12% of all lymphomas. Its
incidence varies widely, from 1.5% in Vancouver, British
Columbia, Canada, to 18.3% in Hong Kong. This may in part
reflect increased exposure to pathogenic factors, such as
human T-cell leukemia virus-1 and Epstein-Barr virus
(EBV), in Asia [7-9]. Although NHL accounts for 2.3% ofKo OB, et al. T-NHL in Korea    129
all cancers in Korea, the incidence of T-cell NHL has not
been determined accurately.
The International Prognostic Index (IPI) and age-
adjusted IPI (AAIPI) are established scoring systems that
predict survival in patients with aggressive NHL [4].
However, the data from which these indices were derived
were obtained primarily from studies performed in
Western countries. Therefore, the IPI may not be directly
applicable to Asian populations, in which the incidence of
EN disease is higher than in Western populations [6,10].
Therefore, we retrospectively assessed the relative fre-
quency and clinical features of T-cell NHL in Korean
patients, and examined the validity and usefulness of
the IPI/AAIPI in Koreans.
METHODS
Patients
Between April 1998 and December 2003, 586 patients
aged 15 years or older were diagnosed with histologically
confirmed NHL at Asan Medical Center, Seoul, Korea. Of
these, 101 patients were diagnosed with T-cell NHL and
treated with the appropriate modality. We retrospectively
reviewed their clinical records, including patient age, sex,
date, and site of diagnostic biopsies, histologic subtype
and EN sites of involvement, performance status, IPI and
AAIPI scores, laboratory/radiological data, and Ann Arbor
stage.
Clinical staging and methods
Clinical stage, including patient history and physical
examination (including Waldeyer’s ring), was determined
using the Ann Arbor classification. Laboratory data
reviewed included a complete blood count, renal function
tests, serum electrolytes, liver function tests, serum lactate
dehydrogenase (LDH), β2-microglobulin concentrations,
and bone marrow aspiration with a trephine biopsy.
Radiological data consisted of chest X-rays and computed
tomography (CT) of the chest, abdomen, pelvis, and pri-
mary site of presentation. In selected patients, additional
evaluations were performed, including magnetic resonance
imaging (MRI) of the brain and spine, panendoscopy and
gastroscopy, and positron emission tomography (PET).
Definitions of nodal and extranodal lymphoma
Lymphomas with clinically dominant lymph node
involvement were considered primary nodal (NL) lym-
phomas, whereas those with primary extranodal involve-
ment or a manifestation of extensively disseminated sys-
temic disease were considered extranodal (EN). Primary
EN lymphomas (PENL) were defined as those presenting
with EN involvement and no or only minor lymph node
involvement. Lymphomas with extensive disease involving
both nodal and EN sites were considered nodal lym-
phomas [11]. 
Histological evaluation
All histological specimens were reviewed by a single
pathologist (Jooryung Huh) and diagnosed according
to the World Health Organization/Revised European-
American Lymphoma (WHO/REAL) system [12].
Statistical analysis
The overall survival (OS) was defined as the time from
the date of diagnosis to death from any cause or last follow
-up visit. Survival curves were estimated according to the
Kaplan-Meier method [13] and compared using the log-
rank test. The log-rank test was also used for univariate
determinations of the correlation between individual
clinical features and OS [14]. Multivariate analyses using
the Cox proportional hazards model were performed with
factors found to be potentially predictive of survival in
univariate analyses [15]. A p value <0.05 was considered
significant. All statistical analyses were performed using
SPSS version 12.0 (SPSS Inc., Chicago, IL).
Table 1. Patient characteristics
Characteristic No. (%)
Age, years
Median 50
Range 15-81
Sex
Male 68 (67.3)
Female 33 (32.7)
B symptoms 50 (49.5)
Elevated serum LDH 99 (98.0)
Performance status (ECOG)
0, 1 89 (88.1)
≥2 12 (11.9)
Stage
I 33 (32.7)
II 15 (14.9)
III 16 (15.8)
IV 36 (31.6)
LDH, lactate dehydrogenase.130 The Korean Journal of Internal Medicine Vol. 24, No. 2, June 2009
RESULTS
Patient characteristics
Of the 586 patients with NHL, 101 (17.2%) were diag-
nosed with T-cell NHL; Table 1 shows their baseline
characteristics. Their median age was 50 years (range
15-81 years), and the ratio of males to females was 2.06:1.
B symptoms were observed in 50 patients (49.5%) and
serum LDH was elevated in 99 (98.0%). Eastern Coope-
rative Oncology Group (ECOG) performance status was 0-
1 in 89 patients (88.1%) and 2-4 in 12 patients (11.9%).
According to the Ann Arbor classification, 33 (32.7%), 15
(14.9%), 16 (15.8%), and 36 (31.6%) patients were stage 1
to 4, respectively.
Table 2 and Figure 1 show the baseline histology of the
patient population. Thirty-four patients (33.6%) had
extranodal NK/T-cell lymphoma, nasal type (NASAL), 30
(29.8%) had peripheral T-cell lymphoma, unspecified
(PTCL-U), and 10 (10%) had anaplastic large cell lym-
phoma, T/null cell, primary systemic type (ALCL). In
addition, 64 patients (63.4%) had PENL in T-cell NHL
(total of 101 patients), similar to the 294 patients (60.6%)
with PENL in B-cell NHL (total of 485 patients).
Overall survival
Figure 2 shows the OS for all patients. With a median
follow-up of 38.4 months, the median OS was not reached.
The 5-year survival rate was 62%. The median follow-up
for the 67 surviving patients was 38.4 months (range 7.2-
80.4 months). Figure 3 shows the OS according to T-cell
NHL subtype. The seven pathological subtypes seen in
this study could be classified into three prognostic sub-
groups: favorable, intermediate, and unfavorable. Patients
with cutaneous ALCL (ALCL-C) were classified as favor-
able, with a 5-year OS of 100%. Patients with PTCL-U,
ALCL, precursor T-cell lymphoblastic lymphoma (T-LBL),
and NASAL were classified as intermediate, with a 5-year
OS of 60-70%. Patients with enteropathy-type T-cell
Table 2. Histology of T-cell NHL
Histologic subhype
PENL NL Total
(n=64) (n=37) (n=101)
EN NK/T-cell lymphoma, nasal type 34 (33.6%) 34 (33.6%)
Peripheral T-cell, unspecified 13 (12.9%) 17 (16.9%) 30 (29.8%)
Anaplastic large cell, systemic 3 (3.0%) 7 (7.0%) 10 (10.0%)
Precursor T-cell, lymphoblastic 6 (6.0%) 6 (6.0%)
Angioimmunoblastic T-cell 1 (1.0%) 5 (5.0%) 6 (6.0%)
Enteropathy-type T-cell 2 (2.0%) 2 (2.0%)
Other 11 (10.6%) 2 (2.0%) 13 (12.6%)
EN, extranodal; PENL, primary extranodal lymphoma; NL, nodal lymphoma.
Figure 1. Histology of T-cell NHL. NASAL, extranodal NK/T-cell
lymphoma, nasal; PTCL-U, peripheral T-cell lymphoma, unspec-
ified; ALCL, anaplastic large cell lymphoma, T/null cell, primary
systemic type; T-LBL, precursor T-cell lymphoblastic lymphoma;
AITL, angioimmunoblastic T-cell lymphoma; ETTL, enteropathy-
type T-cell lymphoma; ALCL-C, ALCL-cutaneous.
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Figure 2. Overall survival of all patients.
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lymphoma (ETTL) and angioimmunoblastic T-cell
lymphoma (AITL) were classified as unfavorable, with a
5-year OS of 50%.
Prognostic factors
The IPI consists of five risk factors: age >60 years,
lactate dehydrogenase (LDH) >upper limit of normal
(ULN), ECOG performance status >1, stage III or IV
disease, and >1 extranodal site. We assessed the validity
and usefulness of the IPI/AAIPI in patients with the three
most frequent subtypes of T-cell NHL (NASAL, PTCL-U,
and ALCL), which accounted for 78% of our patients with
T-cell NHL. Figure 4 shows the OS relative to IPI risk
factors. We found that tumor stage (p=0.0133) and EN
involvement (p=0.0005) were significantly associated
with OS, whereas age (p=0.86), LDH (p=0.13), and
performance (p=0.38) were not. We also found that the
number of EN sites was significantly related to OS
(p=0.0017). The OS of patients with the NASAL, PTCL-U,
and ALCL subtypes of T-cell NHL was significantly
associated with the IPI score (p=0.007). The median OS
of the low-risk group was not reached. The median OS of
the low-intermediate, high-intermediate, and high-risk
groups was 41, 10, and 10 months, respectively. When we
applied the AAIPI to our patients, we found that this index
was also significantly associated with OS (p=0.043). Using
this index, however, we found that the number of patients
was highest in the low-intermediate risk group, followed
by the low, high, and high-intermediate risk groups, in
decreasing order.
Univariate analysis showed that factors predicting
unfavorable OS included tumor stage, EN involvement,
and greater number of EN sites. Multivariate analysis
showed that a greater number of EN sites was the only
independent prognostic indicator for patients with the
three most frequent subtypes of T-cell NHL in Korea
(p=0.042).
DISCUSSION
Over the last two decades, the incidence of NHL in
Korea has increased. This trend is likely due to improve-
ments in diagnostic techniques, including the widespread
use of CT, MRI, endoscopy, and PET. Moreover, the
Table 3. Relative frequency of T-cell NHL
Subtypes International Korean Korean This study
[NHLCP] [Ko et al.] [Kang et al.]
Total cases 247 367 246 101
NASAL 7.8 35 34.1 33.6
AITL 6.7 4 5.2 5.9
PTCL-U 60.8 37.3 45.1 29.7
ALCL 13.4 5.9 6 14.8
T-LBL 6.3 11.5 8.1 8.1
Other 5 6.3 1.5 7.9
T/total 17.9 25.2 30.7 17.2
NASAL, extranodal NK/T-cell lymphoma, nasal; AITL, angioimmunoblastic T-cell lymphoma; PTCL-U, peripheral T-cell lymphoma,
unspecified; ALCL, anaplastic large cell lymphoma, T/null cell, primary systemic type; T-LBL, precursor T-cell lymphoblastic lymphoma;
NHLCP, Non-Hodgkin’s Lymphoma Classification Project.
Figure 3. Overall survival (OS) according to histology. The seven
pathological subtypes observed could be classified into three
prognostic subgroups (favorable, intermediate, and unfavorable)
with respect to the OS. NASAL, extranodal NK/T-cell lymphoma,
nasal; PTCL-U, peripheral T-cell lymphoma, unspec-ified; ALCL,
anaplastic large cell lymphoma, T/null cell, primary systemic type;
T-LBL, precursor T-cell lymphoblastic lymphoma; AITL,
angioimmunoblastic T-cell lymphoma; ETTL, enteropathy-type T-
cell lymphoma; ALCL-C, ALCL-cutaneous.
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availability of safer anesthetics, leading to more frequent
and extended biopsies, including those performed in
elderly and frail patients, is also a factor. In addition,
immunophenotypic, cytogenetic, and molecular analyses
have enhanced diagnostic capabilities and improved the
classification and prognostication for patients with T-cell
NHL [16].
Assessments of the epidemiology and geographical
distribution of NHL in different countries have shown
that the relative frequency of different NHL subtypes in
Korea was similar to that in other Far East countries, but
distinct from that in Western countries [17-22]. For
example, follicular lymphoma has a greater incidence
in North America, the United Kingdom, and South Africa
Figure 4. Overall survival according to the International Prognostic Index (IPI) score. Low-risk, IPI score 0, 1; low-intermediate risk, IPI
score 2; high-intermediate risk, IPI score 3; high-risk, IPI score 4, 5.
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(31%) than in other countries (14%). Peripheral T-cell
lymphoma was most common in London, Cape Town,
and Hong Kong (9%), whereas other cities had much
lower incidences (average 3%) [12,23]. Less is known
about the incidence of NHL subtypes in Korea. Although
clinical studies have examined the incidence of B-cell
NHL subtypes in Korea, none have examined T-cell NHL.
The latter has been reported only as case series, making
it difficult to compare the incidence in Korea with that in
other countries. Overall, the National Cancer Registry of
Korea has reported that NHL accounted for 2.3% (2,246
patients) of all Korean patients with cancer in 2002
(99,025 patients) [24].
Table 3 compares our results, including the clinical
features and distribution of histopathology, with those
previously reported in Korea and Western countries
[5,8,25]. In 1997, the proportion of patients with NHL in
Western countries with T-cell NHL was 17.9%, and the
three most frequent subtypes were PTCL-U (60.8%),
ALCL (13.4%), and NASAL (7.8%). Case series reported
in 1997 and 1998 found that the proportion of patients
with NHL in Korea who had T-cell NHL was higher (25.2
and 30.7%) than in Western countries. While PTCL-U was
the most common subtype in Korea, its relative frequency
(34.1-45.1%) was lower than in Western countries. In
contrast, the incidence of NASAL was higher (34.1-35%)
in Korea than in Western countries. Compared to these
earlier findings, we found that the proportion of patients
with NHL in Korea who had T-cell NHL was lower (17.2%),
similar to that in Western countries, and that NASAL was
the most frequent subtype. Moreover, the incidence of
PTCL-U decreased, while that of ALCL increased greatly,
from 6 to 14.8%. Furthermore, the prognosis of patients
with ALCL differed between Korea and Western coun-
tries. In Western countries, patients with ALCL have a
more favorable prognosis. Moreover, patients with ALCL
who are positive for anaplastic lymphoma kinase (ALK)
have a significantly more favorable prognosis than those
negative for ALK, with 5-year OS rates of 79% and 46%,
respectively [26,27]. In contrast, Korean patients with
ALCL have a less favorable prognosis [27]. However, these
patients were not tested for ALK; therefore, we could not
evaluate the significance of a positive ALK.
Primary extranodal lymphomas have a diverse etiology,
pathogenesis, pattern of presentation, and outcome [28].
In Western countries, at least one-quarter of NHL arises
primarily at EN sites, and these countries show great
geographical variation in the incidence of EN lymphomas.
Less is known about the incidence of NHL in developing
countries [29,30]. In Korea, two-thirds of patients with
NHL have EN involvement at the initial presentation, a
finding confirmed here (63.4%) [10]. The incidence of
PENL was much higher than that observed in the United
States, Hong Kong, Japan, and Taiwan [5,18,21,31,32]. In
particular, Koreans have higher rates of aggressive NHL
and T-cell lymphomas, especially NASAL. This may be
due to the higher incidence of EBV infection in Koreans,
although further studies are needed to determine the true
causes of these geographic differences [7,16].
The IPI scoring system was developed to predict survival
in patients with aggressive NHL [4]. We assessed the
validity and usefulness of the IPI/AAIPI in patients with
the three most frequent subtypes of T-cell NHL: NASAL,
PTCL-U, and ALCL. We found that two components of
the IPI were significantly associated with the OS: stage
(p=0.0133) and EN involvement (p=0.0005). In addition,
the OS in patients with the NASAL, PTCL-U, and ALCL
subtypes of T-cell NHL was associated with the overall
IPI (p=0.007) and AAIPI (p=0.184) scores. Although we
do not illustrate the application of the AAIPI, the medial
OS according to subgroup was different: low-risk, high-
risk, low-intermediate, and high-intermediate in decreas-
ing order. Since the AAIPI does not include EN involvement
as a factor, serious drawbacks exist to its use in Korea,
where the incidence of EN involvement is higher than in
Western populations. We found that the number of EN
sites was significantly related to the median OS (p=
0.0017), and multivariate analysis showed that a greater
number of EN sites was the only independent prognostic
indicator of OS among Korean patients with the NASAL,
PTCL-U, and ALCL subtypes of T-cell NHL (p=0.042).
Our study has several important limitations, including
its retrospective design and the inclusion of patients from
a single center. Therefore, to confirm our results, per-
forming a prospective, multicenter study is necessary. A
second limitation was the absence of immunophenotypic,
cytogenetic, and molecular analyses, including assays for
ALK and abnormal cytogenetics. A third limitation was
our inability to calculate the progression-free survival
time, since the patients were treated using various
modalities. For the same reason, we could not estimate
treatment-related toxicities and mortalities.
In conclusion, the relative frequency of T-cell NHL in
Korea seems to be decreasing, becoming more similar to
that of Western countries, although the NASAL subtype
remains frequent in Korea. Western patients with the134 The Korean Journal of Internal Medicine Vol. 24, No. 2, June 2009
ALCL subtype have a more favorable prognosis than
Korean patients. In assessing patient prognosis, the IPI
scoring system should not be applied uniformly to Korean
populations, although this system was developed to
predict survival in patients with aggressive NHL. In
addition, our results indicate that the number of EN sites
is a significant factor. Therefore, our findings suggest the
need for large-scale studies of Korean patients with T-cell
NHL.
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